Nicotine addiction (NA) is a common and devastating disease, such that the annual number of deaths (world-wide) from tobacco-related diseases will double from 5 million in the year 2000 to 10 million in 2020. Nicotine is the only substance in tobacco which animals and humans will self-administer. NA, as a lifetime diagnosis, has been assessed in various approaches, including the concept of cigarettes per day (CPD). Other assessments of NA are somewhat more comprehensive, such as the Fagerstrom Test for Nicotine Dependence or the American Psychiatric Association's Diagnostic and Statistical Manual (fourth edition) diagnosis of nicotine dependence. These different measures have moderate agreement with one another. Twin, family and adoption studies have shown that these different assessments of NA have substantial heritability (that fraction of risk attributable to genetic factors). The heritability of NA has been estimated at 50-75%, depending on the definition and the population under study. DNA-based studies of NA have been somewhat successful in identifying a common haplotype, which increases risk for NA among European-origin populations. This haplotype explains a small amount of variance, accounting for B1 CPD, and it includes the a5 and the a3 nicotinic receptor subunit genes (CHRNA5 and CHRNA3 ). The review will focus on this implicated region. In this risk region, there is a common (among European-origin people) missense single-nucleotide polymorphism in the CHRNA5 gene (D398N), which changes a conserved amino acid from aspartic acid to asparagine. The risk allele (398N) confers decreased calcium permeability and more extensive desensitization, according to in vitro cellular studies, raising the possibility that a positive allosteric modulator of the (a4b2) 2 a5 type of nicotinic receptor might have therapeutic potential in NA. There are other genetic influences on NA in this region, apart from the mis-sense variant, and additional biological experiments must be done to understand them.
Epidemiology of nicotine addiction
Annual global deaths from tobacco-related diseases will double from 5 million in the year 2000 to 10 million in 2020, 1,2 if current trends continue. Among American adults, B20% are regular cigarette smokers and B13% are nicotine addicted (NA). 3 NA is a complex phenotype, as with any addiction. Assessments of NA include a nicotine dependence diagnosis (Figure 1 ) in the Diagnostic and Statistical Manual for Mental Disorders 4th edition. The Fagerstrom Test for Nicotine Dependence (FTND) 4 ( Figure 2 ) is a briefer tool, heavily weighted for cigarettes per day (CPD) and time from waking until the first cigarette. These measures relate to tolerance and withdrawal. Lessov et al. 5 analyzed multiple NArelated phenotypes in a large twin study. They concluded that the CPD variable has one of the highest genetic loadings among NA phenotypes. This CPD phenotype may be a quantitative measure of tolerance and addiction, and may be a simple phenotype for genes contributing to NA risk, as chronic smokers achieve a level of CPD that would have been toxic when they initiated smoking. Another NA-related phenotype is pack-years, an expression of duration of heavy smoking, calculated by multiplying the mean number of packs (a pack contains 20 cigarettes) smoked per day by smoking years. The Diagnostic and Statistical Manual for Mental Disorders 4th edition NA has a limited correlation with the FTND, 4 or with CPD. [6] [7] [8] [9] The FTND is a measure that focuses on physiological dependence and tolerance, whereas Diagnostic and Statistical Manual for Mental Disorders 4th edition NA includes cognitive and behavioral aspects of addiction (for example, use despite evidence of harmful effects).
Abundant data from twin and adoption studies provide evidence for the heritability of habitual cigarette smoking. Hall et al. 10 reviewed twin and adoption data in smoking studies, including five studies of twins reared apart. Taken together, these twin studies suggest that a majority of NA risk is attributable to genetic factors. More recent twin smoking research 5, 11, 12 suggests that the heritability of NA is B75%.
Linkage analysis in nicotine addiction
An initial genome linkage scan for NA in B380 NA kindreds was conducted by Straub et al., 13 who described suggestive linkage on chromosomes 2 and 10. Swan et al. 14 found suggestive linkage on chromosomes 6, 7 and 8 for various measures related to NA. A study of African-Americans found evidence of linkage for several phenotypes related to NA on chromosomes 9q31, 11p11 and 13q13. 15 Gelernter et al. 16 found linkage for a NA-related phenotype in
an African-American sample on chromosome 5 and in a European-American sample on chromosome 7. Vink et al. 17 also published linkage data for NA in Dutch kindreds. There have been multiple linkage analyses of the Framingham study data for smoking variables. 18, 19 The chromosome 9 locus implicated in the Framingham study 19 has been the subject of fine mapping, with the GABAB2, NTRK2 and SHC3 genes implicated by association analysis. 20 Significant evidence for linkage of NA to chromosome 22q12 was reported by Saccone et al. 21 in which two sets of multiplex kindreds of Australian and Finnish ancestry were examined. This study is notable for the significant LOD score and concordance between the two data sets. No NA linkage studies reported significant LOD scores for the CHRNA5 region.
Candidate gene association studies of nicotine addiction
Although many candidate gene and linkage studies have been published for NA (for a review, see Li 22 ), most have not been replicated consistently, due to small sample sizes, small effect sizes of single alleles/ haplotypes and genetic heterogeneity (reviewed in Hirschhorn and Altshuler 23 ). For example, SNPs in the a4 subunit of the cholinergic nicotinic receptor (CHRNA4) were associated to NA in a Chinese population 24 and in African-American and Europeanorigin populations. 25 The DOPA decarboxylase gene 26, 27 and the GABAB2 receptor gene 28 were associated to NA in American populations. Similarly, the CHRNB1 gene has also been implicated in an association study of NA. 29 COMT variants were associated with NA. 30 The validity of these associations will be driven by the extent to which they are confirmed in similar populations. In the EuropeanAmerican populations, which were the subject of several GWAS reports [31] [32] [33] (totaling B140 000 subjects), confirmation at genome-wide levels of significance was not observed for these genes. Some of these candidate gene associations may be specific to certain ethnic groups or be characterized by very small effect sizes. Additional research will be necessary.
Genome-wide association study of nicotine addiction
A NA genome-wide association study (GWAS), 8 and candidate gene 34 study of B1000 cases and B900 controls of European ancestry provisionally identified several SNP alleles in the CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15 (several SNPs with 0. 0001 < P < 0.01) as conferring risk. In the context of a GWAS, however, these P-values are not considered statistically significant, as they might arise randomly at least B100 times. Berrettini et al. 9 described a GWAS of B7000 individuals of European origin for CPD, with a P-value B10 À5 , at a CHRNA3 SNP allele. They studied a second population of equal size, for the same phenotype (CPD), reporting association to a second allele in the same haplotype (P-value B10 À6 ), establishing the common European haplotype as conferring risk for NA. Simultaneously, Thorgeirsson et al. 35 implicated the same SNP alleles in a large Icelandic/European study, with P = 10 À20 . Weiss et al. 36 reported association of early-onset NA to this same haplotype in an US sample (P = 10 À4 ). Bierut et al. 37 ; Caporoso et al.
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; and Keskitalo et al.
39
provided additional confirmation of the role of this haplotype in NA through study of independent European-origin populations of heavy smokers. All of these studies used DNA from people of European ancestry, and all were consistent with a small effect, odds ratio B1. 8, 36 inability to quit when pregnant, 40 early onset of tobacco use, 36, 41 serum cotinine (a nicotine metabolite) level 39, 42 and chronic obstructive pulmonary disease in a GWAS report. 43 There are three independently associated groups of highly correlated SNPs, each of which contributes to the associative signals at the CHRNA5-CHRNA3-CHRNB4 gene cluster. 44 The results of three GWAS meta-analyses [31] [32] [33] did not identify SNPs in the CHRNB4 gene as contributing to the genetic association signal for nicotine addiction. Likewise, whereas Saccone et al. 45 found a nominal association of rs12914008 in CHRNB4 in Figure 3 Haplotype structure of CHRNA5-CHRNA3 genes in Europeans. Haploview 4.2 92 was used to download the version 2, release 21 CEU data set between Chr15:76630000-76705000 from the HapMap project. The method of Gabriel et al.
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(i.e., confidence intervals) was used to generate haplotype blocks. The relative positions of SNPs 1-58 along each gene is shown schematically at the top. In all five major ( > 5%) and two rare ( < 5%) haplotypes of the gene cluster are shown with risk alleles in each haplotype associated with NA boxed in black. The first or 00 risk 00 haplotype contains multiple SNPs associated with NA including a mis-sense coding SNP (cSNP) (rs16969968-(A)) in CHRNA5 and a synonymous cSNP (rs1051730-(T)) in CHRNA3 (Note: The alleles for CHRNA3 are those of the opposite strand such that, for example, rs1051730 is an 'A' rather than a 'T'). The 'mixed' haplotypes (second and fifth) contain many SNPs associated with NA, but not rs16969968-(A) or rs1051730-(T) (Note: The only difference between the second and fifth 'mixed' haplotypes shown is at rs1948 in CHRNB4. Thus, the 'mixed' haplotypes have a combined frequency of 24.2 þ 5.8% = 30% as defined in Berrettini et al.
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). The third and fourth haplotypes are considered 'protective,' containing no SNPs associated with NA. The sixth and seventh 'rare' haplotypes also have a mixed allele structure with respect to SNPs associated with NA. Note that because it is not in the HapMap data set, rs3841324 is not shown in the haplotype block structure shown in Figure 3 , but it is associated strongly with the 'mixed' haplotype(s).
European-American smokers, this same CHRNB4 gene SNP was not relevant to this genetic signal after correction for multiple testing in a meta-analysis, 44 although the power to detect an association was minimal owing to a low minor allele frequency for this SNP. Thus, whereas b4 subunit expression in medial habenula may contribute to murine nicotine aversion 46 genetic variation within CHRNB4 in European-American populations of smokers does not seem to explain any detectable variance in the nicotine addiction phenotype. Although it is theoretically possible that the patterns of LD across these three genes could implicate CHRNB4 SNPs, the preponderance of functional evidence 37,47-50 centers on CHRNA5 and CHRNA3 as containing three sets of alleles associated with nicotine addiction.
Many of the same CHRNA3 and CHRNA5 NA risk alleles have been associated (P = B10
À8
) with lung cancer risk 35, [51] [52] [53] in four GWAS reports. There have been candidate gene positive reports as well, 54, 55 giving rise to commentaries on the nature of the biological mechanisms of these associations. 56 The implicated CHRNA5 and CHRNA3 genes are expressed in lung tissue epithelium. The increased lung cancer risk may be partially independent of the NA risk, as the lung cancer cases and controls were matched for smoking histories. The risk for lung cancer due to CHRNA5 alleles may be related to a 30-fold upregulated CHRNA5 transcription in lung cancer tissue 57 and the anti-apoptotic effect of nicotine on lung cancer cells. 58 Epigenetic modification of the CHRNA3 promoter may also be important in determining the escape from apoptosis by lung cancer cells, as tumors show hypermethylation of the promoter. Furthermore, re-activation or overexpression of CHRNA3 in lung tumor cells induces apoptosis. 59 In the presence of nicotine, premalignant lung epithelial cells may escape an apoptotic signal from the immune system, through activation of CHRNA5-containing nicotinic receptors.
However, there may be a component of the CHRNA5-related lung cancer risk, which is dependent on smoking. Risk for lung cancer does increase linearly with CPD, and there is evidence that individuals with the NA risk alleles smoke more CPD than those without; 9,35 they may extract more nicotine from cigarettes by smoking more intensively, than those without these risk alleles, 39 perhaps increasing their exposure to the carcinogenic components of cigarette smoke.
Given the numerous reports of association with alleles of this common European haplotype, investigators reasoned that meta-analyses of large numbers of cases and controls in the context of GWAS genotyping would yield additional loci. Several efforts [31] [32] [33] combined to yield more than 140 000 samples. These were analyzed for CPD, ever versus never smoking status, age at initiation and quit status. The results were disappointing in the sense that there were no alleles of even modest effect, beyond those at the CHRNA5-CHRNA3 locus. Nevertheless, a few loci of very small effect seem promising, including rs4105144 31 (P = 10 À12 ), near CYP2A6, which encodes a nicotine-metabolizing enzyme. Variants in CYP2A6 have been associated with smoking behavior previously. 60 Thus, these NA risk alleles have been studied intensively, with the clear result that they increase risk for several NA-related phenotypes (FTND and CPD), lung cancer and chronic obstructive pulmonary disease.
Molecular biology of nicotinic receptors
Nicotine's rewarding effects appear to be mediated through distinct subunits of nicotinic acetylcholine receptors (nAChRs), encoded by different genes and expressed in discrete regions in the brain. 61 These nAChRs are pentomeric structures, with a central ion channel core. 61 Multiple nicotinic receptor subunit genes, in alpha (a2-a9) and beta (b2-b5) groups, have been identified. 62 Of particular interest are the a4 and b2 subunits, which combine to make a neuronal nAchR and are expressed in the mesolimbic dopamine system and the a7 subunit, present in hippocampus and cortex, regions involved in learning, memory and emotion. 62, 63 a5 (CHRNA5) subunits are typically found associated with some a3 (CHRNA3) and a4 nicotinic receptor subunits.
62 a5 and a3 subunits are obligate accessory subunits, which cannot form functional nAChRs by themselves or in combination with only one other type of subunit. They do not form acetylcholine binding sites, and assemble in a position similar to that of b1 subunits of muscle nAChRs (Figure 4 ). a3 and a5 subunits are expressed in regions of human brain involved in reward, learning, motor co-ordination, emotion and memory: nucleus Figure 4 Shown are the structures of multiple pentomeric nicotinic receptors. Note that the a5 subunit can substitute for a b2 subunit, whereas the a3 subunit can substitute for a a4 subunit.
accumbens, entorhinal cortex, cerebellum and amygdala, among others (www.genelogic.com).
In the NA risk region, there is a functional missense common G/A (D398N) SNP in exon 5 (rs16969968) of the CHRNA5 gene ( Figure 5 ). Among European-origin populations, this SNP has B35% minor allele (A, encoding asparagine) frequency. This allele is uncommon (frequency B1-5%) among Asian and African populations (www.hapmap.org). 37, 45, 55, 64 The allele changes a highly conserved amino-acid residue, aspartate, to asparagine. The 'A' allele (encoding N) is the risk allele for NA.
PolyPhen-2 is a web-based computer program (http://genetics.bwh.harvard.edu/pph2/) to predict possible impact of an amino-acid substitution on the structure and function of a human protein. It uses straightforward physical and evolutionary comparative considerations. When this program is used to compare the two protein isoforms of the a5 protein, the program predicts the substitution (D398N) to be benign.
When the two forms of the human a5 subunit (N398 and D398) were expressed in Xenopus oocytes, using human a4 and b2 subunit genes in a concatamer structure, the Ca þ þ permeability was measured as % maximal response to 10 mM acetylcholine, 49 as shown in Figure 6 . The NA-associated risk allele, N398, demonstrated reduced maximal response, compared with the wild-type, D398. This result was observed only when the a5 subunit was combined with a4 and b2 subunits, but was not seen when a3 subunits were combined with a5 subunits. This result is qualitatively similar to an earlier study, which involved expression in HEK293T cells of human a5 subunits with mouse a4 and b2 subunits. 37 In addition, Kuryatov et al. 49 also showed that the % desensitization at 3 s, after exposure to 3 mM acetylcholine, was significantly greater for the NAassociated N398 form of the (a4b2) 2 a5 acetylcholine receptor, compared with the protective D398 form (46 versus 22%, P = 0.015). Again, the desensitization difference was only seen in the (a4b2) 2 a5 receptors, but not in other configurations, containing a3 subunits or b4 subunits. These observations of decreased Ca þ þ flux and increased desensitization suggest that the N398 (a4b2) 2 a5 acetylcholine receptor isoform may increase NA risk by conveying hypofunction of the (a4b2) 2 a5 acetylcholine receptor. These results imply that a positive allosteric modulator at these N398 (a4b2) 2 a5 acetylcholine receptors might correct the putative NA-associated N398 (a4b2) 2 a5 acetylcholine receptor hypofunction.
The NA risk-conveying 'A' allele at SNP rs16969968 is uncommon among African, native American and Asian populations (www.hapmap.org). 37, 45, 55, 64 It may be possible that other variants within the implicated haplotype increase risk for NA among these ethnic groups. Large numbers (for example, > 10 000) of African or Asian smokers have not yet been assessed for influence of this haplotype on smoking behavior. Shiraishi et al. 55 reported that the European risk haplotype was associated with lung cancer and smoking among Japanese, even though the allele frequency was B1%. Other SNPs (for example, rs667282 in CHRNA3) are associated with lung cancer risk among Chinese peoples. 65 
Genetic animal models of nicotine addiction relevant to the CHRNA5 locus
The CHRNA3-null mutant mice are not viable, 66 and the heterozygote has not been studied for NA phenotypes. The CHRNA5-null mutant mouse has a decreased nicotine-elicited dopamine release from nucleus accumbens in vitro.
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The a5 subunit may be responsible for transmission of some aversive effects of nicotine in the medial habenula. 68 These investigators demonstrated that CHRNA5-null mutant mice self-administered more nicotine intravenously than wild-type mice ( Figure  7 ). They also demonstrated that this effect could be blocked by injection of lentivirus constructs containing the a5 subunit cDNA into the medial habenula of the CHRNA5-null mutant mice. These authors concluded that nicotinic receptors containing a5 subunits in the medial habenula were responsible for transmission of some aversive qualities of nicotine. Thus, the NA CHRNA5 risk allele, which is partially deficient in signaling, 49 may allow for greater appreciation of nicotine reward in relation to aversive effects of nicotine.
Clearly, other nicotinic receptor subunits are involved in the rewarding and/or aversive effects of nicotine. Indeed, whereas common human genetic variation in some subunits, such as CHRNB3-CHRNA6, detected in GWA and association studies of nicotine addiction, 21 ,31 may influence risk for NA, others that were not detected by these genetic studies likely also influence NA. For example, the b2 (CHNRB2) subunit may be critical to the rewarding effects of nicotine. Picciotto et al. 69 reported that nicotine can stimulate dopamine release in brains of wild-type mice, but mice lacking the b2 subunit show no such increase in extracellular dopamine following nicotine treatment. In self-administration experiments, nicotine can be substituted for cocaine in wild-type mice, but not in the b2 knockout mice. These experiments suggest that the b2 subunit may be involved in signaling the rewarding effects of nicotine. When a supersensitive a4 subunit was created and introduced into the mouse, nicotine was rewarding at very small doses (which did not convey reward in wild-type mice), suggesting that nAChRs containing a4b2* (where * indicates inclusion of b2, a4 or a5 subunits) configuration are sufficient for nicotine reward, tolerance and sensitization. 70 
CHRNA5 regulation and expression
There are a number of polymorphisms in the CHRNA5 promoter and 5 0 UTR that may influence its expression levels. Buckland et al. 71 found that a 22-bp deletion (rs3841324-(D)) had no effect on transcription in TE671 cells, but decreased transcription by B40% in HEK293T cells. Similarly, Falvella et al.
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reported that in three of the four lung cancer cell lines examined, rs3841324-[D] caused an B80% decrease in CHRNA5 promoter-derived luciferase activity. Wang et al. 47 and Falvella et al. 72 evaluated steadystate CHRNA5 mRNA expression levels in postmortem brain and resected lung tissue, respectively. In contrast to the in vitro findings, these ex vivo studies suggested that individuals who were homozygous for the 22 base pair deletion (rs3841324-(D)) allele in CHRNA5 generate B2.5-3 times greater steady-state CHRNA5 mRNA levels in vivo; with higher levels being associated with the intronic CHRNA5 SNP rs588765-(T) allele in the Wang et al. 47 study. The rs3841324 deletion encompasses a small number of transcription factor binding sites, including SP-1. 71, 73 Whereas other factors that regulate brain expression by binding within the CHRNA5 promoter deletion cannot be excluded, the loss of the binding site for SP-1, which stimulates transcription, could explain the decreased in vitro transcriptional activity from the CHRNA5 rs3841324 deletion constructs in most cell types, but not the enhanced activity observed in vivo. 47, 72 Interestingly, Saccone et al. 44 observed a reversal of the allelic effect when rs588765 was studied by itself (rs588765-(C) allele increased risk) or in joint analysis with rs16969968 (rs588765-(T) allele increased risk). In addition, when the intronic SNP rs588765 and cSNP rs16969968 (D398N) in CHRNA5 are studied together they define three common haplotypes in European-Americans with different effects on risk, 44 perhaps on the basis of differences in expression levels of CHRNA5. 47 Smith et al. 48 reported the presence of putative distal promoter enhancer elements that drive expression of the 'protective' rs16969968-(G) allele and noted that SNPs rs880395, rs7164030 and rs905740 within this putative enhancer element are in 'substantial LD' with rs3841324. Thus, in a heterozygous (rs16969968-(A/G)) individual, the relative risk would depend 
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The CHRNA5-A3-B4 gene cluster WH Berrettini and GA Doyle on both the genotypes at rs3841324 and these distal promoter SNPs. However, direct analysis of this distal promoter region in heterologous promoter constructs revealed a strong repressor effect and no apparent difference in repressor strength between the major and minor haplotypes at rs880395, rs7164030 and rs905740. 50 A recent meta-analysis of NA genome-wide association studies revealed a strong association signal from rs58853698 in the CHRNA5 5 0 UTR. 32 Falvella et al. 72 observed a trend toward B2.0-fold less activity of the 'TGG' (risk) versus 'ATC' (protective) haplotype constructs in lung cancer cell lines, where rs503464 (À166W), rs55853698 (À123K) and rs55781567 (À76S) are the SNPs in the haplotype. When promoter sequences were held constant, Doyle et al. 50 also observed an effect of variation at rs55853698 and rs55781567 on luciferase activity in human BE-2C neuroblastoma cells; presumably owing to a translational affect. Thus, in addition to rs16969968, overall risk for NA in populations of European ancestry must be assessed based on the contributions of other SNPs within the extended haplotype of CHRNA5, including rs880395, rs7164030, rs905740 and rs503464 in the CHRNA5 promoter, as well as rs55853698 and rs55781567 in the 5 0 UTR, which may influence expression levels of CHRNA5 mRNA, and perhaps also of a5 protein.
CHRNA5-CHRNA3-CHRNB4 in alcohol addiction
There is a substantial co-morbidity between nicotine and alcohol addiction; and there is evidence that nAChRs of various subtypes interact with ethanol. [74] [75] [76] Rats treated with varenicline, a partial agonist at a4b2* nAChRs and partial antagonist at a3b4* nAChRs, drink less alcohol and show decreased levels of reinstatement. 77 As such, some human genetic studies have investigated the potential role of either the a5, a3 or b4 nAChR subunits in determining alcohol addiction. Wang et al. 78 did a family-based association test in the Collaborative Study on Genetics of Alcoholism sample set. Whereas risk for NA is defined by a common haplotype in European-Americans (Figure 3) , with SNPs that are in high LD, those that associate with risk for alcohol addiction appear to be different, being in lower LD with those SNPs found to associate with nicotine addiction. For instance, of the CHRNA5 mis-sense cSNP rs16969968 and the CHRNA3 synonymous cSNP rs1051730, which are in high LD (r 2 X0.9) with each other in European-Americans and are associated with increased NA risk (Figure 3) , only rs1051730 showed a weak, but significant association (FDR q-value = 0.042) with alcohol addiction in the European-American Collaborative Study on Genetics of Alcoholism data set. 78 This result is intriguing, because association with alcohol addiction was not seen for the highly correlated cSNP rs16969968 in CHRNA5. Indeed, all of the SNPs associated with alcohol addiction in the Wang et al. The SNPs associated with alcohol addiction in the European-American sample population include the indel polymorphism in the CHRNA5 promoter (rs3841324), which was found to affect CHRNA5 expression levels. 72, 78 However, in African-Americans, whereas there was no genetic association between rs3841324 and alcohol addiction, the association between a highly correlated (r 2 = 0.8) intronic SNP (rs588765) in CHRNA5 was maintained. This observation led Wang et al. 78 to suggest that SNPs associated with alcohol addiction might be within the boundaries of intron 1 of CHRNA5 (marked by rs588765) and intron 5 of CHRNA3 (marked by rs6495307, but bounded by rs3743077), which would not exclude rs1051730 in CHRNA3. Interestingly, Joslyn et al. 79 reported that the minor allele at rs1051730 in CHRNA3 associated with three measures of alcohol level of response: the body sway anterior/posterior, self-report of the effects of ethanol and subjective high assessment scale. Whereas the minor allele at rs1051730 tags the missense cSNP rs16969968 (D398N) in CHRNA5, direct genotyping of this SNP did not show association with alcohol addiction in the European-American population of the Collaborative Study on Genetics of Alcoholism sample. 78 These findings suggest that other SNPs in strong LD with rs1051730, or rs1051730 itself, might confer increased risk for alcohol use disorders and addiction. Indeed, Joslyn et al. 79 found that associated SNPs within extended haplotypes fell into two groups: rs1051730 (in CHRNA3), rs8034191 and rs3885951 (in LOC123688), rs12594247 (5 0 of CHRNB4) and rs1394371 (5 0 of IREB2) versus rs6495306 and rs680244 (in CHRNA5), rs8192475 (in CHRNA3), rs950776 (in CHRNB4), rs4887053 and rs12903150 (5 0 of IREB2), and rs13180 (in IREB2). The former SNPs demonstrated minor allele associations with decreases in at least one measure of alcohol level of response, whereas the latter SNPs showed minor allele associations with increased alcohol level of response. Taken together, these studies suggest that the two addictions share some common, as well as different risk alleles in the CHRNA5-CHRNA3-CHRNB4 gene cluster.
Further support for the potential involvement of CHRNA3 (and/or CHRNB4) in alcohol addiction comes from a recent paper showing that a partial agonist (CP-601932) for the a3b4* nAChRs decreases ethanol consumption and seeking in rats. 80 One caveat to the studies by Steensland et al. 77 and Chatterjee et al. 80 is that at the doses used, varenicline and CP-601932 not only act as partial agonists at a3b4* nAChR subtypes, but also act as antagonists at a4b2* nAChR subtypes. Thus, it remains unclear which receptor subunits, or subtypes, are functionally responsible for the two addictions in vivo. Nevertheless, both varenicline and CP-601932 have been used as smoking cessation therapies and may have utility in decreasing ethanol consumption in smokers as well.
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Pharmacogenetics of smoking cessation
Finally, as cessation of addictive behaviors is the ultimate goal of genetic and pharmacogenetic studies, we will end with a short review of the current literature in this area of the NA field. Several studies have attempted to determine the genetics and pharmacogenetics of smoking cessation, including multiple GWAS. 33, 82, 83 These GWAS did not implicate the CHRNA5-A3-B4 gene cluster. Rather, other genes that attained genome-wide significance for smoking cessation were identified, including DBH, which catalyzes the conversion of dopamine to norepinephrine. 33 As with the GWAS, a study of cessation rates among B1500 German heavy smokers revealed no associations with SNPs or haplotypes of the CHRNA5-CHRNA3-CHRNB4 gene cluster. 84 Likewise, an extensive study of SNPs and haplotypes within this gene cluster of a Korean population for associations with smoking initiation, smoking quantity and smoking cessation showed only nominal significance between some SNPs and haplotypes and smoking cessation that were not upheld after Bonferroni correction for multiple testing. 64 However, a study of smoking cessation among pregnant women in the UK found a notable signal of (P = 0.0006; P = 0.018 when corrected for pre-pregnancy smoking levels) association between rs1051730 in CHRNA3 and quit rates without therapeutic intervention. 40 This finding has been confirmed in another population (OR = 1.24, P = 0.0018). 85 Whereas the GWAS did not identify the CHRNA5-A3-B4 gene cluster as being significant in smoking cessation (including nicotine replacement therapy), other studies have implicated at least one of these genes in response to other pharmacological agents for smoking cessation. For example, Heitjan et al. 86 took a Bayesian approach to identifying SNPs within the CHRNA and CHRNB gene families in response to bupropion smoking cessation therapy. This study found that a SNP (rs871058) in the first intron of CHRNA5 was associated with a strong therapeutic response to bupropion in people with the common allele at rs871058; however, this finding was not replicated. 87, 88 In another smoking cessation study, using both bupropion and transdermal nicotine replacement therapies, response-to-therapy at week 6 or 1 year was dependent on the minor alleles at rs680244 (in CHRNA5 intron 1) or rs12914008 (in CHRNB4 exon 3), respectively. 89 Moreover, there was an effect of genotypes at rs8192475 (in CHRNA3 exon 2) on craving and withdrawal in the acute phase of treatment; however, this effect was only seen in one of the two treatment paradigms used in this study. 89 Thus, the role of the various subunits encoded by the CHRNA5-A3-B4 genes in treatment response to pharmacotherapies for smoking cessation remains unclear. Larger pharmacogenetic studies of smoking cessation agents with these alleles must be undertaken.
One caveat for pharmacogenetic studies of smoking cessation deserves mention. The CHRNA5/3 risk alleles increase slightly the CPD among NA individuals (see above). It is often observed in smoking cessation studies that persons with higher CPD (or FTND) values find it more difficult to quit. 90, 91 Thus, the CHRNA5/3 risk alleles may be weakly associated with smoking cessation in reflection of this fact, but this association may be independent of the pharmacological mechanism of the agent(s) under study.
Summary
Abundant epidemiological data indicate that NA is a common, devastating and partially inherited disease. GWAS and candidate gene studies have led to the identification of NA risk alleles in the CHRNA5-CHRNA3-CHRNB4 cluster of nicotinic receptor subunits genes on chromosome 15q25. One such functional allele is the 'A' allele of the D398N mis-sense G/A SNP in CHRNA5. The 'A' allele is the NA risk allele, encoding N. Electrophysiologic studies of this SNP in Xenopus oocytes revealed a calcium permeability hypofunction effect, such that a positive allosteric modulator might correct the allelic difference. Additionally, there is much greater % desensitization for the N ('A' nucleotide) allele, again emphasizing a hypofunction. This is a promising beginning in terms of genetically based therapeutics for NA.
The CHRNA5 region conveys a small effect on risk for NA. Nevertheless, it is a promising drug target, given that there is considerable pharmacological knowledge concerning nicotinic receptors. Available evidence suggests that increasing (a4b2) 2 a5 acetylcholine receptor function may increase the aversive experience of nicotine, limiting the drive to smoke. Development of pharmaceutical agents that accomplish this would add another agent to the pharmacological options to reduce smoking and thereby improve public health. Notably, the National Institute on Drug Abuse has issued a request for applications to develop medications in light of this opportunity (www.nida.nih.gov).
